Nucala Market Expected To Grow Steadily And Approach $1.01 Billion By 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Nucala Market Be By 2030 Compared To Its 2026 Market Size?

Historically, the observed growth has stemmed from several factors, including an escalating incidence of severe eosinophilic asthma, a heightened awareness and identification of eosinophilic conditions, the broadening scope of biologic treatment protocols, enhanced diagnostic capabilities for measuring eosinophil levels, and the expansion of prescribing by medical specialists.

The anticipated expansion during the projected timeframe stems from a greater reach into various eosinophilic conditions, a heightened need for tailored respiratory biologics, progress in monoclonal antibody engineering, more extensive global reimbursement policies, and a rise in at-home treatment options. Key developments expected over this period encompass the growing acceptance of targeted biologic treatments for asthma, wider application of IL-5 inhibitors in managing chronic ailments, the broadening of precision medicine strategies in respiratory care, an increased emphasis on sustained disease management, and improved methods for patient categorization.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20300&type=smp

What Key Drivers Are Fueling The Growth Of The Nucala Market?

The escalating incidence of asthma is projected to drive the Nucala market’s expansion moving forward. Asthma is a chronic condition affecting the respiratory system, characterized by inflamed and narrowed airways, resulting in symptoms like wheezing, coughing, chest tightness, and shortness of breath, often triggered by allergens or physical activity. The rise in asthma cases is linked to factors such as environmental pollution, allergens, evolving lifestyles, urbanization, and genetic susceptibility. Nucala effectively manages asthma by targeting and inhibiting interleukin-5 (IL-5), a crucial protein involved in the proliferation and activation of eosinophils, which are white blood cells that contribute to airway inflammation in asthma, thus alleviating symptoms and reducing the frequency of exacerbations. For example, in February 2023, as per NHS England, a UK-based government department, in the UK, 5.4 million people receive asthma treatment, with approximately 160,000 new diagnoses annually, and work-related asthma accounts for 9-15% of adult-onset cases. Consequently, the increasing prevalence of asthma is stimulating growth within the Nucala market. The growing frequency of eosinophilic disorders is expected to fuel the Nucala market’s progression. Eosinophilic disorders encompass various medical conditions marked by an excessive production and accumulation of eosinophils, a type of white blood cell, in different tissues, leading to inflammation and potential harm. The rising occurrence of eosinophilic disorders is attributed to elements such as increasing environmental allergens, shifts in dietary patterns, genetic predispositions, and enhanced awareness leading to better diagnostic rates. Nucala (mepolizumab) addresses eosinophilic disorders by specifically targeting and inhibiting interleukin-5 (IL-5), a cytokine essential for the growth and survival of eosinophils, thereby decreasing eosinophil levels and easing associated symptoms. For instance, in December 2023, according to PubMed, a US-based government-operated, non-profit online database, the global pooled incidence and prevalence of EoE were reported as 5.31 cases per 100,000 inhabitant-years. Thus, the increasing prevalence of eosinophilic disorders is propelling growth in the Nucala market.

Which Segment Categories Are Included In The Nucala Market Segment Analysis?

The nucala market covered in this report is segmented –

1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Chronic Obstructive Pulmonary Disease (COPD), Other Eosinophilic Disorders

2) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies

3) By End User: Hospitals, Clinics, Home Care Settings

What Trends Are Affecting The Direction Of The Nucala Market?

Major companies engaged in the Nucala market are concentrating on developing innovative solutions, such as ready-to-use injectable formulations, to satisfy the increasing demand for patient convenience and improved treatment adherence. A ready-to-use injectable form constitutes a pre-prepared pharmaceutical product that necessitates no further dilution or mixing prior to its administration. For instance, in May 2025, GlaxoSmithKline Plc, a UK-based pharmaceutical company, secured approval from the US FDA for Nucala (mepolizumab) for the management of adults with chronic obstructive pulmonary disease (COPD) exhibiting an eosinophilic phenotype. This expansion of indication enables targeted therapy for COPD patients with a considerable unmet need, supported by favorable results from the MATINEE and METREX Phase III trials.

Who Are The Active Companies Shaping The Nucala Market?

Major companies operating in the nucala market are GlaxoSmithKline plc

Get The Full Nucala Market Report:

https://www.thebusinessresearchcompany.com/report/nucala-global-market-report

Which Region Accounts For The Largest Portion Of The Nucala Market?

North America was the largest region in the nucala market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucala market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Nucala Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/nucala-global-market-report

Browse Through More Reports Similar to the Global Nucala Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795